Sex differences in motor response to levodopa in early Parkinson’s disease
Objective: To evaluate differences between males and females in trajectory of motor response to levodopa in early Parkinson’s disease (PD). Background: Previous research has shown…From the Healthy Brain Ageing – HeBA – Cohort: Motivation for participating in the first online phase of HeBA
Objective: We aim to understand the motivation of participants to join the first online-phase of the European multicenter Healthy Brain Ageing (HeBA; see Abstract 0748_1125_001612)…Habenula Volume in Mood Disorders in Parkinson’s Disease
Objective: To assess whether dysregulation of habenula (Hb) contributes to mood disorders in Parkinson’s disease (PD). Background: PD is often accompanied by mood disorders, such…SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models
Objective: Validate the rescue potential of SLP-2 induction for α-synuclein (aSyn)-induced mitochondrial pathology and neurodegeneration in two complementary models: human induced pluripotent stem cell (hiPSC)-derived…Retrospective exploration of the 5-2-1 criteria in clinical practice
Objective: To explore documentation in medical records (EMRs) of the 5 (5 oral levodopa doses taken/day) -2 (2hours of OFF time/day) -1 (1 hour of…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development
Objective: The objective of these studies is to develop a tissue engineered nigrostriatal system involving human dopaminergic and striatal cells to recapitulate many of the…The effect of dopaminergic medication on force fluctuation in Parkinson’s disease
Objective: To quantify and compare muscle force variability during isometric dorsiflexion in male patients with Parkinson's Disease (PD), in the ON- versus OFF-medication state. Background:…Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…The Roche ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development – Focus on Parkinson’s disease
Objective: To develop an ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development to increase the probability of success of clinical trials in Parkinson’s disease. Background:…
- « Previous Page
- 1
- …
- 355
- 356
- 357
- 358
- 359
- …
- 553
- Next Page »